Current clinical trials of hepcidin antagonism are primarily centered around malignancy induced anemia of chronic disease and other hematological disorders, although quinoxaline, a small molecule that prevents degradation of the ferroportin receptor was shown to have in vitro activity against the MCF7 breast cancer cell line [153,158]. Here, HAMP is linked to anemia (phenotype).